Analysts See $-0.11 EPS for Xenon Pharmaceuticals Inc. (XENE)

February 15, 2018 - By Ellis Scott

 Analysts See $ 0.11 EPS for Xenon Pharmaceuticals Inc. (XENE)

Analysts expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to report $-0.11 EPS on March, 14.They anticipate $0.21 EPS change or 65.63 % from last quarter’s $-0.32 EPS. After having $-0.43 EPS previously, Xenon Pharmaceuticals Inc.’s analysts see -74.42 % EPS growth. The stock decreased 1.89% or $0.07 during the last trading session, reaching $3.63. About 11,148 shares traded. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has declined 39.94% since February 15, 2017 and is downtrending. It has underperformed by 56.64% the S&P500.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Ratings Coverage

Among 5 analysts covering Xenon Pharmaceuticals (NASDAQ:XENE), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Xenon Pharmaceuticals had 14 analyst reports since August 11, 2015 according to SRatingsIntel. The company was upgraded on Wednesday, August 19 by Zacks. Jefferies reinitiated the shares of XENE in report on Friday, October 30 with “Buy” rating. The company was maintained on Monday, June 12 by Jefferies. Jefferies reinitiated it with “Buy” rating and $13 target in Monday, March 13 report. Guggenheim initiated Xenon Pharmaceuticals Inc. (NASDAQ:XENE) on Monday, September 26 with “Buy” rating. The rating was maintained by Jefferies on Wednesday, March 9 with “Buy”. The company was upgraded on Tuesday, August 11 by Zacks. The company was maintained on Monday, September 11 by Jefferies. The company was maintained on Tuesday, August 11 by Canaccord Genuity. The stock of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has “Buy” rating given on Friday, October 21 by Stifel Nicolaus.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company has market cap of $65.33 million. The firm uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It currently has negative earnings. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency.

More notable recent Xenon Pharmaceuticals Inc. (NASDAQ:XENE) news were published by: Globenewswire.com which released: “Xenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare …” on April 26, 2017, also Globenewswire.com with their article: “Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial” published on October 17, 2017, Globenewswire.com published: “Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update” on March 08, 2017. More interesting news about Xenon Pharmaceuticals Inc. (NASDAQ:XENE) were released by: Globenewswire.com and their article: “Xenon Pharmaceuticals Outlines Key Milestones for 2018” published on January 08, 2018 as well as Marketwatch.com‘s news article titled: “Xenon Pharmaceuticals Inc.” with publication date: October 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.